Option Care Health Surges 34% on $5.8B CD&R and McKesson Buyout
CD&R and McKesson have agreed to acquire Option Care Health in a $5.8 billion deal, sending OPCH shares soaring 34% on the news.
Option Care Health shares rocketed 34% after the company confirmed it had reached a definitive agreement to be acquired by private equity firm Clayton, Dubilier & Rice and healthcare distribution giant McKesson in a deal valued at approximately $5.8 billion. The dramatic single-session move reflects the substantial premium typically embedded in leveraged buyout offers, signaling that acquirers see meaningful upside in the home and alternate-site infusion therapy market that Option Care Health dominates.
The pairing of CD&R — one of the most active healthcare-focused private equity players — with McKesson, a top-tier pharmaceutical distributor, is strategically telling. McKesson's existing infrastructure in drug logistics and specialty pharmacy gives the combined ownership group natural operational leverage over Option Care Health's nationwide infusion network, potentially unlocking cost synergies and expanded referral pipelines that a standalone public company might struggle to achieve at the same pace.
Read more Hardware Wallet Supply Chain Trust Is Under Fresh Scrutiny →
The transaction also arrives at a moment when the home infusion therapy sector is attracting intensified investor and strategic interest. An aging U.S. population, persistent pressure on hospital capacity, and insurer incentives to shift complex drug administration out of expensive inpatient settings have all accelerated demand for exactly the services Option Care Health provides. For McKesson, a stake in a leading infusion provider represents a downstream integration play that could deepen its relationships with pharmaceutical manufacturers and payers alike.
For existing OPCH shareholders, the 34% jump effectively crystallizes years of operational progress into an immediate liquidity event, a dynamic that often leaves some long-term holders debating whether the offer fully captures the company's trajectory. Whether competing bids emerge or the deal closes as structured will be the central question for investors watching the stock in the weeks ahead.
Continue reading at SeekingAlpha.
